SO-005A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer. (2nd July 2019) - Wainberg, Z; Boland, P; Lieu, C; Dayyani, F; Macarulla, T; Zhang, B; Belanger, B; Moore, Y; Wang, T; Maxwell, F; Dean, A